Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review article examines the current understanding of frontal fibrosing alopecia, noting its prevalence in different demographics and the roles of genetic and environmental factors in its pathogenesis, while highlighting that treatment approaches remain varied and lack standardization.

This cohort study found no overall increased risk of suicidal behaviors with finasteride versus dutasteride in men aged 50 and older, but suggested potential risk for those with a history of mood disorders.

This review discusses sex differences in Parkinson's disease and highlights that while men are more frequently affected, androgen-modulating treatments have not yet proven effective for PD, though 5α-reductase inhibitors show potential for further study.

In this South Korean retrospective study, dutasteride improved hair growth more effectively than finasteride in men with androgenic alopecia, and had a similar or possibly lower rate of adverse events, suggesting it as a viable treatment option.

This study suggests that type I 5-alpha reductase may also play a role in hair growth, with dutasteride potentially being more potent than finasteride in modulating key hair growth gene expressions.

This review discusses various treatment options for androgenic alopecia, noting finasteride's greater efficacy in men and identifies ongoing research needs, particularly for therapies like laser and stem cells.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

This review covers androgenetic alopecia's epidemiology, pathogenesis, current management options, and research trends, concluding that no definitive cure exists despite extensive interest and ongoing genetic research efforts.

This review discusses current treatment options for androgenetic alopecia, noting that most lack robust evidence for efficacy and safety, highlighting the need for more comprehensive studies.

This review examines the sexual side effects of 5α-reductase inhibitors like finasteride, highlighting the increased risk of erectile dysfunction, libido reduction, and potential contribution to depression without new clinical findings.

This review discusses techniques for harvesting follicular units, medical treatments for androgenetic alopecia, and potential future advancements in hair restoration therapy, but it reports no new clinical results.

This article reviews the Clinical Pearls presentation format introduced at the American College of Physicians' 2001 meeting for its effectiveness in applying practical clinical tips, but provides no new empirical results.

This chapter discusses the increasing prevalence of overactive bladder in aging men, examining potential causes and treatment options, without reporting new clinical results.

This study consisted of a pharmacy master's thesis detailing practical experiences during a hospital and community pharmacy internship and scientific investigations into the off-label use of dutasteride for androgenetic alopecia and oral vaccines for urinary tract infection prophylaxis, emphasizing therapeutic applications and mechanisms of action.

This research focused on formulating finasteride, dutasteride, and minoxidil with cyclodextrins to enhance their solubility and skin penetration for topical use, potentially reducing scalp irritation from current alcohol-based preparations.

This study found that in healthy young men, oral minoxidil at 5 mg/day led to increased carotid intima-media thickness and vascular aging, suggesting potential cardiovascular side effects at higher doses. A dose-dependent effect was observed, while dutasteride displayed a favorable vascular profile without significant changes.

This study systematically reviewed androgenetic alopecia's clinical features, mechanisms, and treatments, highlighting that current drugs have limitations but emerging therapies and personalized treatment strategies could enhance efficacy and outcomes.

This study used molecular docking simulations to identify approved drugs, including Bedaquiline and Telmisartan, with potential to treat Onchocerca volvulus infections by inhibiting key protein targets, suggesting these drugs could be repurposed for onchocerciasis treatment with further validation.

This study found that long-term use of 5α-reductase inhibitors is associated with improved overall survival in men with renal cell carcinoma, particularly those with low comorbidity not receiving surgery or systemic therapy, suggesting a potential role for androgen modulation in disease management.

This pharmacovigilance study analyzed FAERS data and found that finasteride is more frequently associated with neuropsychiatric reactions like depression and suicide risk, especially in younger men using it for alopecia, compared to dutasteride.

This chapter provides a comprehensive review of androgenetic alopecia, covering its key physiological mechanisms, diagnostic methods, and a variety of treatment options ranging from topical therapies to aesthetic and regenerative procedures, emphasizing recent advances observed in dermatological practice.

This study used molecular docking simulations to identify Adapalene, Diosmin, and Azelastine as promising drugs for repurposing against onchocerciasis by targeting proteins in the parasite and its endosymbiont; further research is needed to confirm their efficacy.

This study reports on a 14-year-old male with refractory diffuse alopecia areata who achieved full hair density restoration after three monthly sessions of microneedling combined with triamcinolone, dutasteride, and synthetic exosome treatment, highlighting exosomes' potential for enhancing traditional therapies in autoimmune hair loss cases.

Finasteride and dutasteride have little effect on Type 2 Diabetes risk.

Pharmacists play a crucial role in improving patient outcomes through personalized care and staying updated with scientific advancements.

Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.

This study reviews current pharmacological treatments for alopecia, highlighting minoxidil, 5α-reductase inhibitors, JAK inhibitors, and other agents, and notes ongoing research aimed at improving their effectiveness and safety profiles.

In this study, the derivation of certain topological indices was used to represent the molecular structure of drugs for alopecia treatment, like Minoxidil and Finasteride, which may support medication investigations, especially in resource-limited settings.

Dutasteride is more effective than finasteride for hair growth, and sublingual apomorphine quickly improves Parkinson's symptoms.

This pilot study found that using skin patting with iontophoresis to deliver dutasteride gel significantly improved hair density, shaft diameter, and pull test scores in men and postmenopausal women with treatment-resistant androgenetic alopecia, with participants reporting high satisfaction and no adverse events.